Role of the factor V Leiden mutation in septic peritonitis assessed in factor V Leiden transgenic mice

被引:21
|
作者
Bruggemann, Lois W. [1 ]
Schoenmakers, Saskia H. H. F. [1 ]
Groot, Angelique P. [1 ]
Reitsma, Pieter H. [1 ]
Spek, Arnold [1 ]
机构
[1] Univ Amsterdam, Acad Med Ctr, Lab Expt Internal Med, NL-1105 AZ Amsterdam, Netherlands
关键词
FV Leiden; sepsis; inflammation; coagulation; animal experiments;
D O I
10.1097/01.CCM.0000228918.30931.E8
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: The factor V Leiden (FVL) mutation (Arg506Glu) results in the production of an FV protein that when activated is relatively resistant to inactivation by activated protein C and thereby leads to predisposition to thrombosis. The rather high prevalence of the FVL mutation in the general population prompted speculation about a potential survival benefit for individuals carrying the FVL allele. Indeed, both clinical and experimental animal data suggest that a heterozygous FVL genotype might protect against the lethal consequences of sepsis. We sought to confirm the survival advantage of heterozygous FVL mice in septic disease. Design. Controlled animal experiment. Setting: Academic research laboratory. Subjects: Wild-type, heterozygous, and homozygous FVL mice subjected to 1 X 10(4) live bacteria as model for septic peritonitis. Interventions. None. Measurements and Main Results. The intraperitoneal injection of E coli led to growth and dissemination of bacteria and provoked an inflammatory response as evident from elevated cytokine levels (interleukin-6, interleukin-10, and tumor necrosis factor-alpha), induced thrombin-antithrombin complex levels, increased granulocyte influx into the peritoneal cavity, liver necrosis, and adhesion of leukocytes to the vessel wall, resulting in approximately 50% mortality after 72 hrs. The FVL genotype had no significant effect on bacterial outgrowth, markers of inflammation (i.e., tumor necrosis factor-alpha levels of 152 [96.2-200],152 [99.7-1745], and 110 [99.7-177] pg/mL in peritoneal lavage fluid at t = 20 hrs for wild-type, heterozygous, and homozygous FVL mice, respectively), thrombin generation (i.e., thrombin-antithrombin complex levels of 19.9 (9.31-37.4],10.4 [6.55-15.8], and 12.6 (8.24-29.0] ng/mL in peritoneal lavage fluid at t = 6 hrs for wild-type, heterozygous, and homozygous FVL mice, respectively), and/or survival (50%, 36%, and 50% for wild-type, heterozygous, and homozygous FVL mice, respectively). Conclusions. The FVL allele has no beneficial effect in mouse septic peritonitis, and the general protective effect of FVL in sepsis needs further investigation.
引用
收藏
页码:2201 / 2206
页数:6
相关论文
共 50 条
  • [21] Absence of the factor V Leiden mutation in Ethiopians
    Abdulkadir, J
    Feleke, Y
    Berg, JP
    Falch, JA
    Odegaard, OR
    THROMBOSIS RESEARCH, 1997, 86 (05) : 431 - 432
  • [22] How old is factor V Leiden mutation?
    Pawar, AR
    Shetty, S
    Ghosh, K
    Mohanty, D
    THROMBOSIS AND HAEMOSTASIS, 2001, 86 (06) : 1591 - 1592
  • [23] Factor V Leiden and prothrombin gene mutation
    Björkman, A
    Svensson, PJ
    Hillarp, A
    Burtscher, IM
    Rünow, A
    Benoni, G
    CLINICAL ORTHOPAEDICS AND RELATED RESEARCH, 2004, (425) : 168 - 172
  • [24] Factor V Leiden gene mutation and preeclampsia?
    Thorp, JA
    Zucker, ML
    Plapp, FV
    Rachel, JM
    Hinkle, C
    JOURNAL OF MATERNAL-FETAL INVESTIGATION, 1997, 7 (01): : 19 - 20
  • [25] Factor V Leiden mutation and pregnancy complications
    Kjellberg, U.
    van Rooijen, M.
    Bremme, K.
    Hellgren, M.
    THROMBOSIS RESEARCH, 2009, 123 : S152 - S152
  • [26] The impact of the Factor V Leiden mutation on pregnancy
    Spina, V
    Aleandri, V
    Morini, F
    HUMAN REPRODUCTION UPDATE, 2000, 6 (03) : 301 - 306
  • [27] Factor V Leiden mutation in Sneddon syndrome
    Besnier, R
    Francès, C
    Ankri, A
    Aiach, M
    Piette, J
    LUPUS, 2003, 12 (05) : 406 - 408
  • [28] Factor V Leiden mutation and Japanese NIDDM
    Odawara, M
    Yamashita, K
    DIABETOLOGIA, 1997, 40 (11) : 1363 - 1364
  • [29] Automation of the factor V Leiden mutation assay
    Reinartz, J
    McGlennen, R
    Olson, D
    AMERICAN JOURNAL OF PATHOLOGY, 1996, 149 (05): : H1 - H1
  • [30] Cardiovascular implications of the factor V Leiden mutation
    Major, DA
    Sane, DC
    Herrington, DM
    AMERICAN HEART JOURNAL, 2000, 140 (02) : 189 - 195